Dora Onely Roblero-Mejía
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dora Onely Roblero-Mejía has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Carlos García-Ausencio
Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico
1 shared publication - Fernando Guzmán-Chávez
Faculty of Chemistry, Food and Biotechnology Department, Universidad Nacional Autónoma de México UNAM, Ciudad Universitaria , Mexico City 04510
1 shared publication - Romina Rodríguez-Sanoja
Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), México City 04510, Mexico
1 shared publication - Sergio Sánchez
Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, México
1 shared publication
Latest Publications
- Open Access
- 5 December 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (12) , 1179
Embleporicin: A Novel Class I Lanthipeptide from the Actinobacteria Embleya sp. NF3
Genome mining has emerged as a revolutionary tool for discovering new ribosomally synthesized and post-translationally modified peptides (RiPPs) in various genomes. Recently, these approaches have been used to detect and explore unique environments as sources of RiPP-producing microorganisms, particularly focusing on endophytic microorganisms found in medicinal plants. Some endophytic actinobacteria, especially strains of Streptomyces, are notable examples of peptide producers, as specific biosynthetic clusters encode them. To uncover the genetic potential of these organisms, we analyzed the genome of the endophytic actinobacterium Embleya sp. NF3 using genome mining and bioinformatics tools. Our analysis led to the identification of a putative class I lanthipeptide. We cloned the core biosynthetic genes of this putative lanthipeptide, named embleporicin, and expressed them in vitro using a cell-free protein system (CFPS). The resulting product demonstrated antimicrobial activity against Micrococcus luteus ATCC 9341. This represents the first RiPP reported in the genus Embleya and the first actinobacterial lanthipeptide produced through cell-free technology.
- 5 December 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (12) , 1179
Open AccessEmbleporicin: A Novel Class I Lanthipeptide from the Actinobacteria Embleya sp. NF3
Genome mining has emerged as a revolutionary tool for discovering new ribosomally synthesized and post-translationally modified peptides (RiPPs) in various genomes. Recently, these approaches have been used to detect and explore unique environments as sources of RiPP-producing microorganisms, particularly focusing on endophytic microorganisms found in medicinal plants. Some endophytic actinobacteria, especially strains of Streptomyces, are notable examples of peptide producers, as specific biosynthetic clusters encode them. To uncover the genetic potential of these organisms, we analyzed the genome of the endophytic actinobacterium Embleya sp. NF3 using genome mining and bioinformatics tools. Our analysis led to the identification of a putative class I lanthipeptide. We cloned the core biosynthetic genes of this putative lanthipeptide, named embleporicin, and expressed them in vitro using a cell-free protein system (CFPS). The resulting product demonstrated antimicrobial activity against Micrococcus luteus ATCC 9341. This represents the first RiPP reported in the genus Embleya and the first actinobacterial lanthipeptide produced through cell-free technology.